Indoco RemediesQ1 FY24

Indoco Remedies Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹224.98Market Cap: ₹2.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Domestic business growth expected at 11%-12% for the full year FY '24, improving from 6.6% in Q1.
  • Emerging Markets: Q1 de-growth seen as one-off; strong order book signals a dramatic turnaround from Q2 onwards.
  • API business: Strong Q1 growth with expectations to sustain momentum throughout the year.
  • Europe: Growth expected to pick up in subsequent quarters with recent EU GMP certification and larger batch sizes.
  • US market: Full-year revenue guidance remains INR280-300 crores despite OAI; ramp-up gradual with new launches and increased production aimed at reaching INR80 crores per quarter by Q3-Q4.
  • New product launches in domestic and chronic therapies contributed INR6.5 crores sales in Q1, more than double last year.
  • Anti-infective and respiratory segments are still normalizing post-COVID with cautious outlook.

See what Indoco Remedies management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
  • The discussion primarily focuses on operational performance, FDA observations, new product launches, and guidance on revenue and margins.
  • No specific comments or guidance about raising capital via debt or equity instruments were made by management during the call.

See what Indoco Remedies management said on order book — free account, 30 seconds.

Capex plans

Yes
- The transcript does not explicitly mention any specific current or future capex or strategic investments. - There is mention of digitization efforts, including Apple iPads for field force, AIML projects for machine automation, document management, and HRMS systems to improve efficiency. - The company acquired Florida Pharmaceutical Products (FPP), a US-based front-end distribution and marketing company, consolidated for one month in this quarter. - The company plans to leverage the FPP acquisition for front-ending some products currently with external partners, aiming for a transition within 3-4 months. - Remediation costs related to FDA observations on Plant 2 and 3 in Goa are ongoing, estimated around INR4 crores per quarter. - No explicit mention of new capital expenditure plans, but focus on expanding manufacturing capabilities with increased batch sizes post EU GMP certification at Baddi plant and product launches from Goa Plant 1 post-warning letter lift. Overall, focus is on strategic acquisitions, digitization, and regulatory compliance investments rather than new large capex.

Track Indoco Remedies — get its next earnings analysis in your feed

How does Indoco Remedies rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisIndoco Remedies
Rev 3Mar 3

How does Indoco Remedies rank in Pharmaceuticals & Biotechnology?

Compare Indoco Remedies against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →